.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Corneal collagen cross-linking (CXL) has been investigated not only for ectatic disease but also as an adjunct in infectious keratitis, where ultraviolet exposure and photoactivated riboflavin may have antimicrobial and tissue-stabilizing effects. A systematic review and meta-analysis identified multiple clinical studies involving bacterial, fungal, Acanthamoeba, and viral keratitis. Across the available literature, reported healing rates were encouraging, but the authors emphasized substantial heterogeneity and a lack of sufficiently robust randomized evidence. The key clinical point is that CXL should not be interpreted as a replacement for appropriate antimicrobial therapy or source control. Instead, it has been studied as an adjunct in selected ulcers, particularly those with progression or stromal melt. Patient selection and organism type matter, and evidence is much less supportive for viral disease. For cornea specialists, the topic is important because it sits at the intersection of infection control, biomechanics, and tissue preservation. Any use outside established protocols should be framed around the limitations of current evidence and the need for close microbiological and clinical monitoring.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Corneal collagen cross-linking (CXL) has been investigated not only for ectatic disease but also as an adjunct in infectious keratitis, where ultraviolet exposure and photoactivated riboflavin may have antimicrobial and tissue-stabilizing effects. A systematic review and meta-analysis identified multiple clinical studies involving bacterial, fungal, Acanthamoeba, and viral keratitis. Across the available literature, reported healing rates were encouraging, but the authors emphasized substantial heterogeneity and a lack of sufficiently robust randomized evidence. The key clinical point is that CXL should not be interpreted as a replacement for appropriate antimicrobial therapy or source control. Instead, it has been studied as an adjunct in selected ulcers, particularly those with progression or stromal melt. Patient selection and organism type matter, and evidence is much less supportive for viral disease. For cornea specialists, the topic is important because it sits at the intersection of infection control, biomechanics, and tissue preservation. Any use outside established protocols should be framed around the limitations of current evidence and the need for close microbiological and clinical monitoring.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
